Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

Health Technology Assessment : HTA
N WaughS Philip

Abstract

In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline. To review the newer agents available for blood glucose control in type 2 diabetes from four classes: the glucagon-like peptide-1 (GLP-1) analogue exenatide; dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin and vildagliptin; the long-acting insulin analogues, glargine and detemir; and to review concerns about the safety of the thiazolidinediones. The following databases were searched: MEDLINE (1990-April 2008), EMBASE (1990-April 2008), the Cochrane Library (all sections) Issue 2, 2008, and the Science Citation Index and ISI Proceedings (2000-April 2008). The websites of the American Diabetes Association, the European Association for the Study of Diabetes, the US Food and Drug Administration, the European Medicines Evaluation Agency and the Medicines and Healthcare Products Regulatory Agency were searched, as were manufacturers' websites. Data extraction was carried out by one person, and checked by a second. Studies wer...Continue Reading

Citations

Mar 14, 2013·Journal of Endocrinological Investigation·M Gallo
May 28, 2014·PharmacoEconomics·Véronique RaimondLise Rochaix
Oct 5, 2011·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Scott KlarenbachEhud Ur
Nov 8, 2011·Bioscience, Biotechnology, and Biochemistry·Ji Young YeoMyeong-Ho Jung
Sep 11, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Chantal MathieuMichael Theodorakis
May 7, 2013·La Presse médicale·Serge Halimi
Nov 2, 2012·The Journal of Emergency Medicine·Getaw Worku HassenCarolina Velez
Jun 2, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·U L MalandaA J Farmer
Jun 19, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Suzanne E MahadyJacob George
Jul 17, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·S R HellerS C L Gough
Mar 31, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·M CharokopouM Roudaut
Jan 18, 2015·Semergen·M Seguí DíazJ A Divisón
Jun 9, 2015·The Lancet. Diabetes & Endocrinology·Avivit CahnStefano Del Prato
Jul 6, 2015·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Helen L MacLaughlinIain C Macdougall
Mar 22, 2015·Journal of Diabetes and Its Complications·Yeganeh Manon KhazraiPaolo Pozzilli
Dec 3, 2014·The Journal of Allergy and Clinical Immunology. in Practice·Eva PérezJosé Carlos García-Robaina
May 13, 2014·Primary Care Diabetes·Karel KostevChristina Heilmaier
Dec 15, 2010·BMC Endocrine Disorders·Deepson S ShyangdanNorman R Waugh
Feb 20, 2015·BMJ Open·Pamela Royle, Norman Waugh
Mar 25, 2015·The Annals of Pharmacotherapy·Linda TranErin E Thompson
Feb 27, 2013·Journal of Diabetes Science and Technology·Sanjeev N MehtaLori M B Laffel
Sep 2, 2011·Journal of Diabetes Science and Technology·David Kerr, Tolulope Olateju
Apr 11, 2015·Clinical Medicine Insights. Endocrinology and Diabetes·Andreas LieblJean-Francois Yale
Nov 2, 2017·Diabetes Technology & Therapeutics·Anoop MisraPadam Singh
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Deepson S ShyangdanAlisa Snaith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.